ClinicalTrials.gg
Enrolling by invitationNCT06997016Updated Oct 15, 2026

Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients

A Phase 4 interventional study of pre-operative carbohydrate drink and Acetaminophen in Postoperative Pain, sponsored by Baylor Research Institute. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Baylor Research Institute · Phase 4, Interventional, and Treatment

How we know

Updated Oct 15, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.

Planned enrollment
85th of 118
60 · median 90
Started
2025
with 4 others
Phase 4
53 of 118
9 open now
Primary completion
2027-06
later than 7 of 12 live
Registered
110th of 118
by date

Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 85th largest by planned enrollment, is one of 5 that started in 2025, is one of 53 in phase 4, reaches primary completion later than 7 of the 12 other live ones, and was the 110th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies testing acetaminophen in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of this interventional study is to learn if an Enhanced Recovery After Surgery (ERAS) protocol works to reduce the need for narcotic pain medications in live donor kidney transplant recipients. The main questions it aims to answer are:

Does the ERAS protocol lower the amount of opioid narcotic medication needed to manage post-surgery pain? Does the ERAS protocol help lower pain scores after surgery? Researchers will compare the ERAS protocol to previous patients where the ERAS protocol was not used to see if the ERAS protocol works to reduce post-surgery pain.

Participants will be asked to:

  • Drink a pre-surgery carbohydrate drink two hours before your surgery.
  • Take a pre-surgery dose of Tylenol by mouth.
  • Take a pre-surgery dose of Gabapentin by mouth.
  • The surgeon will administer a local numbing medication at the surgery site by injection during the surgery.
  • Begin walking with assistance about 12 hours after your surgery.
  • Allow the research staff to collect data about your kidney function. This data will be collected on your postoperative clinic visits, which generally occur about twice weekly for one month. This information will determine your kidney health, need for hospitalization, and side effects that may occur.
03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • transplantation, kidney
  • renal transplantation
  • Enhanced Postsurgical Recovery
  • Recovery, Enhanced Postsurgical
  • pain, postoperative
  • postsurgical pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients
  • over 18 years of age
  • receiving a kidney transplant from a living donor.

Exclusion criteria

Exclusion Criteria:

  • delayed gastric emptying
  • severe type I diabetes
  • allergy to interventional medications
  • pregnancy (this is a normal exclusion for kidney recipients)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Enhanced Recovery Protocol

    This group will receive the following: 50g carbohydrate drink 2 hours prior to surgery 300mg of gabapentin 30 minutes prior to surgery 650mg of acetaminophen 30 minutes prior to surgery 0.25% bupivicaine local anesthetic intraoperatively assisted ambulation 12 hours after surgery

    Dietary Supplement: pre-operative carbohydrate drink · Drug: Acetaminophen · Drug: Gabapentin · Drug: Bupivacaine · Other: Ambulation

  • No intervention
    Control group

    This group is a retrospective review of 30 patients who have undergone a live donor kidney transplant during 1/1/2022-12/31/2024 will be selected and undergo a retrospective chart review for the same data collection points.

Interventions

  • Dietary supplementpre-operative carbohydrate drink

    50 g of carbohydrate drink 2 hours before surgery

  • 650mg acetaminophen 30 minutes prior to surgery

    Also known as: tylenol

  • 300 mg gabapentin 30 minutes prior to surgery

    Also known as: Neurontin, Gralise

  • intraoperative local anesthetic

    Also known as: Marcaine, Sensorcaine

  • OtherAmbulation

    Assisted ambulation 12 hours after surgery

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) (0-10)

    Patient reported pain on a scale from 0 (no pain) to 10 (the worst possible pain)

    Time frame: From enrollment to the end of treatment at 30 days

  2. Narcotic Use

    milligram morphine equivalents (MME)

    Time frame: From enrollment to the end of treatment at 30 days

Secondary outcomes

  1. Adverse Events

    unfavorable medical occurence

    Time frame: From enrollment to the end of treatment at 30 days

  2. Hospital readmission

    readmission to any hospital within 30 days

    Time frame: From enrollment to the end of treatment at 30 days

  3. Length of Stay

    total hospital length of stay

    Time frame: From enrollment to the end of treatment at 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2027, 25 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 25 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jun 2027, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 30, 2025
StartActual
May 5, 2025
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Jun 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Jun 2026→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06997016
Responsible party
Sponsor
First posted
May 30, 2025
Start date
May 5, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Richard Ruiz, MD
principal investigator · Baylor Scott & White All Saints Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Gabapentin · Bupivacaine

Start the discussion